Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo

International Journal of Cancer

Volumn 76, Issue 6, 1998, Pages 897-902

  Yamamoto, Hidenao ^a   Fujimoto, Jiro ^a   Okamoto, Eizo ^a   Furuyama, Jun Ichi ^a   Tamaoki, Taiki ^b   Hashimoto Tamaoki, Tomoko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BUTYRIC ACID; BUTYRIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION; GENES, P53; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; TUMOR CELLS, CULTURED;

EID: 0032503551     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980610)76:6<897::AID-IJC21>3.0.CO;2-Z     Document Type: Article

References (23)

1. BRESSAC, B., KEW, M., WANDS, J. and OZTURK, M., Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (Lond.). 350, 429-431 (1991).
2. CANDIDO, E.P.M., REEVES, R. and DAVIE, J.R., Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14, 105-113 (1978).
3. CHANG, K. SYRJÄNEN, S., KURVINEN, K., SCI, M. and SYRJÄNEN, K., The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Gastroenterology. 88, 174-186 (1993).
4. WAF1. Cancer Res., 55, 4536-4539 (1995).
5. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174 (1994).
6. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
7. 1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
8. HODIN, R.A., MENG, S., ARCHER, S. and TANG, R., Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells. Cell Growth Differentiation, 7, 647-653 (1996).
9. HOLLSTEIN, N., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C., p53 mutations in human cancers. Science, 253, 49-53 (1991).
10. HSU, I.C., TOKIWA, T., BENNET, W., METCALF, R.A., WELSH, J.A., SUN, T. and HARRIS, C.C., p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis, 14, 987-992 (1993).
11. HSU, I.S., METCALF, R.A., SUN, T., WELSH, J.A., WANG, N.J. and HARRIS, C.C., Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond.), 350, 427-428 (1991).
12. JIANG, H., LIN, J., SU, Z.-Z., COLLART, F.R., HUBERMAN, E. and FISHER, P.B., Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9, 3397-3406 (1994).
13. LANDON, S.P., HAWKES, M.M., HAY, F.G., LAWRIE, S.S., SCHOL, D.J., HILGERS, J., LEONARD, R.C.F. und SMYTH, J.F., Effect of sodium butyrate and other differentiation inducer on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Res., 48, 6161-6165 (1988).
14. MIYASHITA, T. and REED, J.C., Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80, 293-299 (1995).
15. MORINAGA, T., SAKAI, M., WEAMANN, T.G. and TAMAOKI, T., Primary structures of human α-fetoprotein and its mRNA. Proc. nat. Acad. Sci. (Wash.), 80, 4604-4608 (1983).
16. NABEYA, Y., LOGANZO, F., JR., MASLAK, P., LAI, L., DE OLIVEIRA, A.R., SCHWARTZ, G.K., BLUNDELL, M.L., ALTORKI, N.K. and KELSEN, D.P., The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer. 64, 37-46 (1995).
17. NORTON, V.G., IMAI, B.S., YAU, P. and BRADBURY, E.M., Histone acetylation reduces nucleosome core particle linking number change. Cell. 57, 449-457 (1989).
18. STEINMAN, R.S., HUFFMAN, B., IRO, A., GUILLOUF, C., LIEBERMANN, D.A. and EL-HOUSEINI, M.E., Induction of p21(WAF1/CIP1) during differentiation. Oncogene. 9, 3389-3396 (1994).
19. SYMONDS, H., KNALL, L., REMINGTON, L., SAENZ-ROBLES, M., LOWE, S., JACKS, T. and DYKE, T.V., p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78, 703-711 (1994).
20. TSUTSUMI, T., IDO, A., NAKAO, K., HAMASAKI, K., KATO, Y., OHTSURU, A., NAKATA, K., TAMAOKI, T. and NAGATAKI, S., Reciprocal regulation of α-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology, 107, 499-504 (1994).
21. VELAZQUEZ, O.C., JABBAR, A., DEMATTEO, R.P. and ROMBEAU, J.L., Butyrate inhibits seeding and growth of colorectal metastasis to the liver in mice. Surgery, 120, 440-448 (1996).
22. XIONG, Y., HANNON, G.J., ZHANG, H., CASSO, D., KOBAYASHI, R. and BEACH, D., p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366, 701-704 (1993).
23. ZENG, Y. and EL-DEIRY. W.S., Regulation of p21/WAF1/CIP1 expression by p53 independent pathways. Oncogene, 12, 1557-1564 (1996).